Calliditas provides setanaxib patent update

Core Points - Calliditas Therapeutics announced the issuance of a patent by the USPTO for the use of NOX inhibitors in cancer treatment, specifically for solid tumors resistant to PD-1 inhibitor immunotherapy, with setanaxib as the treatment agent [1] - The patent is set to expire in 2039 and Calliditas has additional patent applications in various global territories, including a pending application in Europe [1] - The CEO of Calliditas expressed optimism about the extended product protection for setanaxib in oncology and plans for geographical expansion [2] - Positive topline results from a Phase 2 trial for head and neck cancer using setanaxib were reported, showing statistically significant improvements in progression-free survival and overall survival [3] Company Overview - Calliditas Therapeutics is a biopharma company based in Stockholm, Sweden, focused on developing treatments for orphan indications with significant unmet medical needs [4] - The company's shares are listed on Nasdaq Stockholm and its American Depositary Shares are listed on the Nasdaq Global Select Market [4]